BioGaia ABBGLAF 100 Current Ratio is 4.94 as of Mar. 2026, which is 17% below its 10-year median of 5.93. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review. Among 998 Drug Manufacturers companies, BioGaia AB ranks better than 85.97% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BioGaia AB's current ratio for the quarter that ended in Mar. 2026 was 4.94.
BioGaia AB has a current ratio of 4.94. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for BioGaia AB's Current Ratio or its related term are showing as below:
BGLAF'
s Current Ratio Range Over the Past 10 Years
Min: 2.69 Med: 5.93 Max: 16.75
Current: 4.94
During the past 13 years, BioGaia AB's highest Current Ratio was 16.75. The lowest was 2.69. And the median was 5.93.
BGLAF's Current Ratio is ranked better than 85.97% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.995
vs BGLAF: 4.94
BioGaia AB (OTCPK:BGLAF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
BioGaia AB Current Ratio Related Terms
BioGaia AB Current Ratio Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a Current Ratio of 4.94 as of Mar. 2026. This is 17% below median its historical median of 5.93. Over the past decade, BioGaia AB's Current Ratio has ranged from 2.69 to 16.75. According to the industry distribution chart, BioGaia AB ranks #140 out of 998 companies in the Drug Manufacturers industry, placing it in the top 14%.
Is BioGaia AB's Current Ratio too high?
BioGaia AB's current Current Ratio of 4.94 is 17% below median its 10-year median of 5.93. Over the past 10 years, this metric has ranged from a low of 2.69 to a high of 16.75. The Drug Manufacturers industry median Current Ratio is 2.00. BioGaia AB's value of 4.94 is 147.6% above this industry median. Based on the distribution chart, BioGaia AB ranks #140 out of 998 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #140 out of 998 companies for Current Ratio. This places BioGaia AB in the top 14% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. BioGaia AB's value of 4.94 is 147.6% above this benchmark. Historically, BioGaia AB's own Current Ratio has ranged from 2.69 to 16.75 over the past decade. While the company's 10-year median is 5.93 vs. the industry median of 2.00, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Current Ratio of 4.94 is 147.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Current Ratio is 4.94, which is 17% below median its own 10-year median of 5.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current Current Ratio of 4.94. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current Current Ratio is 4.94, which is 17% below median its 10-year median of 5.93 and 147.6% above the Drug Manufacturers industry median of 2.00. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Current Ratio is 4.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
Key valuation signals for BGLAF:
Current Ratio: 4.94 (17% below median its 10-year median of 5.93)
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 147.6% above the Drug Manufacturers median (#140 of 998)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
